FMR1 and fragile X syndrome: A new CB1 receptor neutral antagonist (NESS0327) was recently shown to have the same beneficial effects on Fmr1-KO mice behavior as rimonabant, supporting the CB1 receptor as a target to treat FXS (Gomis-González et al., 2016).